When: CRL or unfavorable label

Then: Wait two trading days; re-underwrite HIV prevention narrative before decision

HOLD existing position; do not add at current levels; wait for 132-140 entry zone

• MACD at plus 4.45, RSI at 69 after touching 74 eight trading days ago, price at 96th percentile of six-month range, riding upper Bollinger Band, testing prior breakdown resistance at 148.18
• Stock has rallied 22 percent year to date in anticipation of FDA approval; binary catalyst largely priced in
• Conservative probability-weighted expected price is 144-146, below current levels (negative expected value setup)
• Management wrote down 9.2 billion on CymaBay acquisition in 2024, then deployed 11.2 billion on undisclosed target producing 12.6 billion impairment in same quarter
• Leverage profile: 138 percent debt-to-equity at year-end 2024 to 223 percent in Q2 2026
• Cash dropped from 9.6 billion to 3.2 billion
• Prediction market pricing 88 percent probability of no Fed rate cuts in 2026, up 2.2 percentage points in a single week
• Sentiment only mildly bullish at 6.2 out of 10 with medium confidence; Reddit completely silent on GILD
• Preferred entry zone: 132-140, not 148; invalidation level: 132 close
• FCF yield: 5.3 percent; dividend yield: 2.21 percent; 50 SMA at 133.69
• 52-week high: 157.29; Upper Bollinger Band resistance: 152.73
• Aggressive analyst's 165-170 target requires stacking three bullish assumptions including break through 52-week high structure

→ vs aggressive: MACD expanding at plus 4.45 alongside RSI at 69 and price at 96th percentile is momentum convergence warning, not 'coiled spring' continuation signal; using one indicator to override four others is selection bias

→ vs aggressive: FDA approval probability 'well north of 80 percent' is already largely priced in given 22 percent YTD rally; clean approval often produces sell-the-news reaction when expectations run ahead

→ vs aggressive: 165-170 price target requires approval plus momentum continuation plus measured move extension plus retest of all-time high structure; not probability-weighted base case but aggressive bull scenario

→ vs aggressive: Calling 11.2 billion acquisition 'forward-looking capital allocation' ignores 9.2 billion CymaBay write-down and 12.6 billion impairment in same quarter on new acquisition; two nine-figure write-downs in three years indicates capital allocation discipline problems

→ vs aggressive: Ignored macro overlay entirely; prediction market pricing 88 percent probability of no Fed rate cuts in 2026 means higher for longer rates compress defensive pharma multiples regardless of company-specific catalysts

→ vs aggressive: Opportunity cost argument ignores third outcome: entering at 148-149 with sell-the-news reaction produces 5-10 percent realized loss heading into Q3 earnings; dividend yield of 2.21 percent doesn't offset 10 percent drawdown

→ vs neutral: Trader's HOLD recommendation is appropriate but framework should be more conservative; 'lean into the catalyst' violates risk management principles for defensive mandate when multiple signals argue for caution

HOLD with defined tactical playbook: maintain core position, don't chase adds at $148-$149, trim 10-15% at $155-$160 on approval pop, add at $144-$146 on pullback, partial starter position for new money at current levels, downgrade trigger at $133.69 close below 50 SMA on rising volume

• MACD expansion is a valid momentum signal but doesn't justify adding at stretched prices—$148 entry with potential pullback to $145 costs 3% before thesis is tested
• Market already pricing 75-80% FDA approval probability, limiting edge from 85% historical approval rate for late-stage HIV assets
• Aggressive $165-$170 target is 'hope dressed up as analysis'—52-week high is $157.29, probability-weighted upside is $152-$158 in reasonable scenario distribution
• Validates $12.6 billion write-down concern—two nine-figure impairments in three years is a pattern, not coincidence; $3.43 billion FCF shows business absorbs mistakes but doesn't excuse capital allocation
• Technical setup is stretched but trend structure intact—most probable outcome is consolidation, not imminent reversal; RSI cooling from 74 to 69 over 8 days is meaningful without being conclusive
• Macro overlay is a real factor—88% no Fed cut probability and rising yields compress present value of long-duration pipeline cash flows
• Sentiment at 6.2/10 with medium confidence and zero Reddit retail confirmation—bullish case is not crowded, supports HOLD rather than BUY
• Core business is defensive low-beta compounder with 5.3% FCF yield and 2.21% dividend, but balance sheet leverage doubled in one quarter; both realities must be sized for
• Sentiment data more important than either extreme acknowledged—mildly bullish with three catalysts is coherent, not 'underappreciated' or 'tepid conviction'

→ vs aggressive: FDA probability argument is vulnerable—market is already pricing 75-80% approval given 22% YTD rally at 96th percentile of 6-month range; edge from 85% historical rate is small while tail risk is unchanged

→ vs aggressive: $165-$170 target is not a price target but 'hope dressed up as analysis'—stacking bull cases on macro headwind, technical resistance, and extended momentum doesn't constitute base case

→ vs aggressive: Acquisition narrative lost credibility—praising 'aggressive forward-looking capital allocation' ignores $12.6 billion write-down in same quarter as $11.2 billion undisclosed purchase

→ vs conservative: Technical setup doesn't mean reversal is imminent—trends can continue from overbought for weeks; most probable outcome is consolidation, not major reversal or clear sell signal

→ vs conservative: Expected value calculation uses subjective probabilities that were self-constructed—pushing negative EV is showing sensitivity to assumptions, not proving the thesis is wrong

→ vs conservative: 'Wait for $132-$140' is too conservative—missing a level that may never come; partial entry now with defined adds is more appropriate